138750-31-9

Usage

Uses

Used in Organic Synthesis:
(R)-3-AMINO-1-PHENYL-PROPAN-1-OL is used as a chiral building block for the synthesis of various organic compounds, leveraging its unique structure and properties to create novel molecules with potential applications in different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (R)-3-AMINO-1-PHENYL-PROPAN-1-OL is utilized as a key intermediate in the development of new drugs, particularly those targeting specific biological pathways or receptors. Its chiral nature allows for the exploration of stereoselective drug interactions and the optimization of drug efficacy and safety.
Used in Biochemical Studies:
(R)-3-AMINO-1-PHENYL-PROPAN-1-OL serves as a valuable tool in biochemical research, enabling scientists to investigate the role of chirality in biological systems and understand the impact of stereochemistry on molecular recognition and binding. This knowledge can contribute to the advancement of targeted therapies and the development of more effective drugs.

Upstream product

• 198561-42-1 (R)-3-acetyloxy-3-phenylpropanenitrile 
• 168465-69-8 (R)-α-(2-azidoethyl)benzenemethanol 
• 614-16-4 Benzoylacetonitrile 
• 21210-43-5 (S)-Methyl mandelate 
• 100306-33-0 (1R)-3-chloro-1-phenylpropanol 
• 127073-84-1 (R)-3-iodo-1-phenyl-1-propanol 
• 115290-78-3 (1R) 3-phenyl-3-hydroxypropyl methanesulfonate 
• 63888-94-8 ethyl 3-(benzyloxy)benzoate 
• 836684-63-0 3-(3-(benzyloxy)phenyl)-3-oxopropanenitrile 
• 27152-63-2 3-(N-Benzylamino)-1-phenylpropan-1-on 
• 185376-75-4 (R)-3-(benzylamino)-1-phenylpropan-1-ol 
• 7781-98-8 ethyl-3-hydroxybenzoate 
• 96-09-3 styrene oxide 
• 100-42-5 styrene 

Downstream Products

• 138614-32-1 (R)-norfluoxetine hydrochloride 
• 570384-27-9 [4-(3-amino-1-phenyl-propoxy)-phenyl]-p-tolyl-methanone 
• 502697-62-3 (R)-(3-hydroxy-3-phenylpropyl)carbamic acid ethyl ester 
• 130194-43-3 (R)-Norfluoxetine 
• 928007-62-9 (R)-N-(3-hydroxy-3-phenylpropyl)-4-methyl-benzenesulfonamide 
• 114247-09-5 (R)-fluoxetine hydrochloride 
• 1316850-19-7 4-phenyl-3,4-dihydro-2H-benzo[4,5]thiazolo[3,2-a]pyrimidine 
• 115290-81-8 (R)-N-methyl-3-phenyl-3-hydroxypropylamine 
• 54910-89-3 (R)-fluoxetine 
• 1316850-18-6 (R)-3-(benzo[d]thiazol-2-ylamino)-1-phenylpropan-1-ol 
• 82857-40-7 rac-tomoxetine hydrochloride 
• 82248-59-7 atomoxetine hydrochloride 
• 191733-30-9 (S)-N-(ethoxycarbonyl)-3-(4-(trifluoromethyl)phenoxy)-3-phenyl-1-propanamine 
• 191733-29-6 (S)-N-(ethoxycarbonyl)-3-(2-methoxyphenoxy)-3-phenyl-1-propanamine 

Relevant academic research and scientific papers

Asymmetric Hydrogenation of β-Secondary Amino Ketones Catalyzed by a Ruthenocenyl Phosphino-oxazoline-ruthenium Complex (RuPHOX-Ru): The Synthesis of γ-Secondary Amino Alcohols

A ruthenocenyl phosphino-oxazoline-ruthenium complex (RuPHOX-Ru) was applied successfully to the asymmetric hydrogenation of β-secondary amino ketones, directly affording the corresponding chiral γ-secondary amino alcohols in up to 99% yield and with 99% ee. Reaction with β-(benzylamino)-1-phenylpropan-1-one could be performed on a gram-scale with a relatively low catalyst loading (up to 2000 S/C). The resulting hydrogenated product could be used for the synthesis of synthetically useful compounds.

SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS

The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

Synthesis and catalytic properties of 4-aryl-2,3-dihydro-4 H -pyrimido[2,3- b ]benzothiazoles for asymmetric acyl or carboxyl group transfer reactions

4-Aryl-2,3-dihydro-4H-pyrimido[2,3-b]benzothiazoles (4-Ar-DHPBs) were synthesized and their catalytic activity and selectivity in kinetic resolution of a secondary alcohol as well as in the Steglich rearrangement and related reactions were evaluated. 4-Aryl-DHPBs showed low enantioselectivity in the acylative kinetic resolution of 1-phenylethanol. Conversely, they catalyzed the Steglich rearrangement with moderate to excellent enantioselectivity, demonstrating the possibility for remote stereocontrol by introduction of a substituent at the 4-position of DHPB.

TREATMENT OF METABOLIC SYNDROME WITH NOVEL AMIDES

The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention.

ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.

Lewis acid-mediated highly regioselective SN2-type ring-opening of 2-Aryl-N-tosylazetidines and aziridines by alcohols

(Chemical Equation Presented) Lewis acid-mediated highly regioselective SN2-type ring-opening of 2-aryl-N-tosylazetidines with alcohols to afford various 1,3-amino ethers in excellent yields with good enantiomeric excess is described. Similar S

Novel phosphorus-containing prodrug

Novel cyclic phosphoramidate prodrugs of parent drugs MH of formula I their use in delivery of drugs to the liver, their use in enhancing oral bioavailability, and their method of preparation are described.

Polymer-supported chiral sulfonamide catalyzed one-pot reduction of β-keto nitriles: A practical synthesis of (R)-fluoxetine and (R)-duloxetine

Enantioselective reduction of β-keto nitriles to optically active 1,3-amino alcohols has been carried out in one step using an excess of borane-dimethyl sulfide complex as a reductant and a polymer-supported chiral sulfonamide as a catalyst with moderate to high enantioselectivity. The facile and enantioselective method to prepare optically active 1,3-amino alcohols to be converted into 3-aryloxy-3-arylpropylamine-type antidepressant drugs (R)-fluoxetine, and (R)-duloxetine is also reported.

Prodrugs for liver specific drug delivery

The present invention is directed towards novel cyclic phosph(oramid)ate prodrugs of alcohol, amine-, and thiol-containing drugs, their preparation, their synthetic intermediates, and their uses. Another aspect of the invention is the use of the prodrugs

Efficient Heterogeneous Asymmetric Transfer Hydrogenation of Ketones Using Highly Recyclable and Accessible Silica-Immobilized Ru-TsDPEN Catalysts

(Matrix presented) Chiral Ru-TsDPEN [N-(p-toluenesulfonyl)-1,2- diphenylethylenediamine]-derived catalysts were first successfully immobilized onto amorphous silica gel and mesoporous silicas of MCM-41 and SBA-15 by an easily accessible approach. The catalyst immobilized on silica gel demonstrated remarkably high catalytic activities and excellent enantioselectivities (up to >99% ee) for the heterogeneous asymmetric transfer hydrogenation of various ketones. Particularly, the catalyst could be readily recovered and reused in multiple consecutive catalytic runs (up to 10 uses) with the completely maintained enantioselectivity.